Reaction

Brain Neoplasm Malignant reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,441 reports · 39 co-occurring drugs

As of the last recalculation, Brain Neoplasm Malignant appears in 4,441 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is RANITIDINE (PRR 25.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranitidine	888	25.9	26.0
Temozolomide	78	17.6	17.7
Ranitidine Hydrochloride	184	16.5	16.6
Lapatinib	27	8.2	8.2
Selinexor	15	8.1	8.2
Lacosamide	60	7.6	7.7
Osimertinib	44	6.5	6.5
Brivaracetam	12	6.3	6.3
Ado-Trastuzumab Emtansine	10	5.6	5.6
Trametinib	28	5.5	5.5
Thalidomide	39	5.0	5.0
Dabrafenib	22	4.9	4.9
Fondaparinux Sodium	8	4.6	4.6
Atovaquone	7	4.1	4.1
Erlotinib	8	3.9	3.9
Levetiracetam	106	3.8	3.8
Alpelisib	7	3.8	3.8
Extended Phenytoin Sodium	12	3.4	3.4
Encorafenib	7	3.3	3.3
Vemurafenib	8	3.1	3.1
Erlotinib Hydrochloride	8	3.0	3.0
Crizotinib	8	3.0	3.0
Diroximel Fumarate	7	2.8	2.8
Levetiracetam In Sodium Chloride	41	2.5	2.5
Levetiracetam Oral	41	2.5	2.5
Levetiracetam Injection	41	2.5	2.5
Olaparib	10	2.2	2.2
Rucaparib	4	2.1	2.1
Umeclidinium Bromide And Vilanterol Trifenatate	7	2.0	2.0
Risankizumab-Rzaa	34	2.0	2.0
Fluticasone Propionate And Salmeterol	17	1.9	1.9
Pazopanib Hydrochloride	11	1.9	1.9
Bevacizumab	50	1.9	1.9
Pertuzumab	11	1.9	1.9
Interferon Beta-1A	73	1.8	1.8
Somatropin	26	1.7	1.7
Gefitinib	3	1.6	1.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	13	1.5	1.5
Peginterferon Beta-1A	3	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.